ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Says positive data collected with scientists at the University of Salamanca, Spain, provides proof "ReNeuron's novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases". Improved delivery can transform effective drug delivery for neurological diseases, such as stroke, Parkinson's Disease and Huntington's disease.
In March, said it has signed several collaboration agreements with a "major" unnamed pharmaceutical company that will focus on the potential of its exosomes to deliver DNA cargoes for expression of therapeutic genes in the brain. Initiated collaboration with University of Salamanca around the same time.
Current stock price: 121.06 pence, up 28% on Monday
Year-to-date change: up 48%
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)